A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics
Oh, Crystal Yuri
Albrecht, Randy A
Nilsson-Payant, Benjamin E
Kim, Seong Min
Zhu, Danni Y
Benam, Kambez H
Gilpin, Sarah E
Gygi, Steven P
Powers, Rani K
Carlson, Kenneth E
tenOever, Benjamin R
Ingber, Donald E
JournalNature Biomedical Engineering
MetadataShow full item record
AbstractThe rapid repurposing of antivirals is particularly pressing during pandemics. However, rapid assays for assessing candidate drugs typically involve in vitro screens and cell lines that do not recapitulate human physiology at the tissue and organ levels. Here we show that a microfluidic bronchial-airway-on-a-chip lined by highly differentiated human bronchial-airway epithelium and pulmonary endothelium can model viral infection, strain-dependent virulence, cytokine production and the recruitment of circulating immune cells. In airway chips infected with influenza A, the co-administration of nafamostat with oseltamivir doubled the treatment-time window for oseltamivir. In chips infected with pseudotyped severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), clinically relevant doses of the antimalarial drug amodiaquine inhibited infection but clinical doses of hydroxychloroquine and other antiviral drugs that inhibit the entry of pseudotyped SARS-CoV-2 in cell lines under static conditions did not. We also show that amodiaquine showed substantial prophylactic and therapeutic activities in hamsters challenged with native SARS-CoV-2. The human airway-on-a-chip may accelerate the identification of therapeutics and prophylactics with repurposing potential.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15665
- Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
- Authors: Park SJ, Yu KM, Kim YI, Kim SM, Kim EH, Kim SG, Kim EJ, Casel MAB, Rollon R, Jang SG, Lee MH, Chang JH, Song MS, Jeong HW, Choi Y, Chen W, Shin WJ, Jung JU, Choi YK
- Issue date: 2020 May 22
- Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 <i>In Vitro</i> and SARS-CoV <i>In Vivo</i>.
- Authors: Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, Reyes HM, Weiss SR, Frieman MB
- Issue date: 2020 Oct 14
- Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
- Authors: Busnadiego I, Fernbach S, Pohl MO, Karakus U, Huber M, Trkola A, Stertz S, Hale BG
- Issue date: 2020 Sep 10
- Biomimetic Human Disease Model of SARS-CoV-2 Induced Lung Injury and Immune Responses on Organ Chip System.
- Authors: Zhang M, Wang P, Luo R, Wang Y, Li Z, Guo Y, Yao Y, Li M, Tao T, Chen W, Han J, Liu H, Cui K, Zhang X, Zheng Y, Qin J
- Issue date: 2020 Oct 24
- Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
- Authors: Yamaya M, Nishimura H, Deng X, Kikuchi A, Nagatomi R
- Issue date: 2020 May